title: Differences in glyoxal and methylglyoxal metabolism determine cellular susceptibility to protein carbonylation and cytotoxicity.
abstract: Chronic hyperglycemia in diabetic patients often leads to chronic side effects associated with protein glycation and the formation of reactive carbonyl species, such as methylglyoxal (MGO) and glyoxal (GO). We have shown that both MGO and GO carbonylated bovine serum albumin (BSA) in vitro to the same degree and stability. The carbonylated BSA formed initially could be a reversible Schiff base as the UV absorbance formed after the addition of 2,4-dinitrophenylhydrazine was decreased when sodium borohydride was added. MGO and GO also carbonylated hepatocyte protein rapidly with similar dose and time dependence. In contrast to BSA carbonylation, the amount of carbonylated proteins in hepatocytes decreased over time, much more rapidly for hepatocytes treated with MGO than with GO. This could be attributed to the rapid hepatocyte metabolism of MGO with glyoxalase I, the predominant detoxification enzyme for MGO. Protein carbonylation and the associated toxicity caused by GO and MGO were studied in the following hepatocyte models: (1) control hepatocytes, (2) glutathione (GSH)-depleted hepatocytes, (3) mitochondrial aldehyde dehydrogenase (ALDH2)-inhibited hepatocytes, (4) hepatocyte inflammation model, and (5) catalase-inhibited hepatocyte model. Carbonylation and cytotoxicity caused by MGO or GO was markedly increased in GSH-depleted hepatocytes as compared to control hepatocytes. Hepatocytes exposed to non-toxic concentrations of H(2)O(2) or hepatocytes treated with catalase inhibitors also showed a marked increase in GO-caused cytotoxicity and protein carbonylation, whereas there were only minor increases with MGO. The GO effect was attributed to potential radical formation and the inhibition effect of H(2)O(2) on aldehyde dehydrogenase, a major GO metabolising enzyme. GO-caused cytotoxicity and protein carbonylation were also increased with ALDH2-inhibited hepatocytes whereas such an increase was only observed with MGO in GSH-depleted hepatocytes.
authors.affiliation: Department of Pharmaceutical Sciences, Faculty of Pharmacy, University of Toronto, Toronto, ON, Canada.
authors.forename: Kai
authors.initials: K
authors.lastname: Yang
authors.forename: Dong
authors.initials: D
authors.lastname: Qiang
authors.forename: Sarah
authors.initials: S
authors.lastname: Delaney
authors.forename: Rhea
authors.initials: R
authors.lastname: Mehta
authors.forename: W R
authors.initials: WR
authors.lastname: Bruce
authors.forename: Peter J
authors.initials: PJ
authors.lastname: O'Brien
mesh_terms: D000444:Aldehyde Dehydrogenase / Q000037:antagonists & inhibitors; D000071396:Aldehyde Dehydrogenase, Mitochondrial; D000818:Animals; D002417:Cattle; D003603:Cytotoxins / Q000378:metabolism* / Q000633:toxicity*; D004791:Enzyme Inhibitors / Q000494:pharmacology; D006037:Glyoxal / Q000378:metabolism* / Q000633:toxicity*; D022781:Hepatocytes / Q000187:drug effects / Q000201:enzymology / Q000378:metabolism; D024101:Mitochondrial Proteins / Q000037:antagonists & inhibitors; D050050:Protein Carbonylation / Q000187:drug effects*; D011765:Pyruvaldehyde / Q000378:metabolism* / Q000633:toxicity*; D051381:Rats; D017207:Rats, Sprague-Dawley; D019163:Reducing Agents / Q000378:metabolism; D012545:Schiff Bases / Q000378:metabolism; D012710:Serum Albumin, Bovine / Q000378:metabolism
chemical_list: D003603:Cytotoxins; D004791:Enzyme Inhibitors; D024101:Mitochondrial Proteins; D019163:Reducing Agents; D012545:Schiff Bases; D012710:Serum Albumin, Bovine; D006037:Glyoxal; D011765:Pyruvaldehyde; D000444:Aldehyde Dehydrogenase; D000071396:Aldehyde Dehydrogenase, Mitochondrial; C505112:Aldh2 protein, rat